Clinical Trials

53 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT06991556 2026-06-02

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

150 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT07198633 2026-06-02

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Phase 1/2 Recruiting

212 enrolled

Phase 3 Not yet recruiting

Advanced Prostate Cancer

NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

5,000 enrolled

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT05367440 2026-06-01

PETRANHA

Phase 1/2 Active not recruiting

174 enrolled

Prostatic Neoplasms

NCT04221542 2026-05-29

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT06863272 2026-05-29

IDeate-Prostate02

Phase 1/2 Recruiting

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07570979 2026-05-28

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

208 enrolled

Prostatic Neoplasms

NCT07611110 2026-05-28

VECTRA-01

670 enrolled

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

1,889 enrolled

Prostatic Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

520 enrolled

Prostatic Neoplasms

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

707 enrolled

Phase 1/2 Enrolling by invitation

Neoplasms, Prostatic Neoplasms

NCT04145375 2026-05-08

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

40 enrolled

Prostatic Neoplasms

NCT04986423 2026-05-08

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT06764485 2026-05-06

rechARge

960 enrolled

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06136624 2026-05-05

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT06551324 2026-05-05

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT04191096 2026-04-29

KEYNOTE-991

Phase 3 Completed

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03768063 2026-04-28

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

13 enrolled

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT03395197 2026-04-22

TALAPRO-2

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT05457257 2026-04-21

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Active not recruiting

43 enrolled 16 charts

Metastatic Castration-resistant Prostate Cancer

NCT04076059 2026-04-17

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT07406282 2026-04-09

Double-DARE

Recruiting

1,400 enrolled

Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Tumor-Agnostic

Neoplasms

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Phase 1 Recruiting

56 enrolled

Prostate Adenocarcinoma

NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Completed

2,731 enrolled 14 charts

Prostatic Neoplasms, Castration-Resistant

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled